Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Q32 Bio Inc.FIXX · Entity 5594 | Chief Operating Officer | July 09, 2019 | July 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Q32 Bio Inc.
Report date July 09, 2019 · Filed July 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 222,707 |
Reported balance
After 2019-07-09 transaction · row 1
1 source rowRow 1 · 2019-07-09 · Sale · Disposed 8,000 · Balance 222,707 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2019 Filed Jul 11, 2019 16:30 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 8,000 | $20.00 | $160,000.00 |
DisclosureSEC source: 0000899243-19-019474 · doc4.xml · nonDerivative · entry 1 Rasty Siyamak · CIK 0001735450 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,707 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 18:09 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 8,000 | $20.22 | $161,777.60 |
DisclosureSEC source: 0000899243-19-015642 · doc4.xml · nonDerivative · entry 1 Rasty Siyamak · CIK 0001735450 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,707 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $20.00 to $20.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 27, 2018 Filed Mar 29, 2018 19:19 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee stock option · Derivative | 30,780 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-18-008919 · doc4.xml · derivative · entry 1 Rasty Siyamak · CIK 0001735450 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,780 Underlying: Common Stock · 30,780 shares Expires 2028-03-27 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following March 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.